Glenmark Launches Zita DM: A Triple-Drug Combination for Type 2 Diabetes for just Rs 14

▴ Glenmark
Glenmark's commitment to providing affordable and effective solutions highlights its role as a leader in diabetes care. As Zita DM becomes a part of the diabetes management landscape, it holds the potential to positively impact the lives of millions of individuals suffering from this chronic condition.

Glenmark Pharmaceuticals Limited, a leading global pharmaceutical company, has introduced a groundbreaking solution for managing type 2 diabetes in India. The newly launched Zita DM is the country's first triple-drug fixed-dose combination (FDC) that combines teneligliptin with dapagliflozin and metformin, addressing the challenges faced by diabetic patients.

India, with the second-largest diabetic population globally, has witnessed the launch of Zita DM to enhance glycemic control in individuals with type 2 diabetes. This FDC, available under the brand name Zita DM, combines the widely-used teneligliptin (20mg), dapagliflozin (10mg), and metformin SR (500mg/1000mg) in a fixed dose, requiring only once-daily consumption under a prescription.

Addressing Unmet Needs: Alok Malik, President & Business Head - India Formulations at Glenmark Pharma, highlighted the challenges faced by type 2 diabetic patients in India, including uncontrolled HbA1c levels and beta cell dysfunction affecting insulin secretion. Zita DM aims to fill this gap by offering a robust solution that not only improves glycemic control but also addresses co-morbidities such as weight gain.

Glenmark's Zita portfolio, catering to around 1.75 million type 2 diabetic patients annually in India, has been a foundation in diabetes management. With the addition of Zita DM, the comprehensive gliptin range promises to assist type 2 diabetic patients at every stage of their treatment journey.

Affordability and Accessibility: Priced at Rs. 14 per tablet, Zita DM is positioned as an affordable anti-diabetic drug. This pricing strategy is expected to lower the daily cost of therapy by 30%, making the medication more accessible to a broader population.

Market Impact and Growth: The oral anti-diabetic drugs market in India, as per IQVIA sales data for the period ending August 2023, is estimated at Rs. 12,522 crore, with an annual growth rate of 6.5%. Zita DM's entry is poised to make a significant impact on this market, offering an innovative and effective treatment option.

Glenmark's Legacy in Diabetes Care: Glenmark has a strong legacy in providing effective and affordable treatment options for patients with uncontrolled type 2 diabetes. The company has consistently introduced innovative drugs and combinations, including DPP4 inhibitors, SGLT-2 inhibitors, and various FDCs, contributing to the evolving landscape of diabetes care in India.

In conclusion, the launch of Zita DM marks a significant milestone in the management of type 2 diabetes in India. Glenmark's commitment to providing affordable and effective solutions highlights its role as a leader in diabetes care. As Zita DM becomes a part of the diabetes management landscape, it holds the potential to positively impact the lives of millions of individuals suffering from this chronic condition

Tags : #glenmark #zitadm #diabetes #diabetescare #diabtesmanagement #FDC #pharmaceutical #medicircle

About the Author


Sunny Parayan

Hey there! I'm Sunny, a passionate writer with a strong interest in the healthcare domain! When I'm not typing on my keyboard, I watch shows and listen to music. I hope that through my work, I can make a positive impact on people's lives by helping them live happier and healthier.

View Profile

Related Stories

14 Sep

Health Ministry signs MoU with Ministry of Social Justice & Empowerment for enhanced outreach on HIV/AIDS prevention

“As health is the responsibility of all Government departments, there is a need for a ‘sub-department of health’ in all the Ministries for health impact assessment of the policies/initiatives of these Ministries right from the conceptual stages.”

View

-Advertisements-




Trending Now

Will India’s Healthcare Budget Support a Future of Robotic Surgeries?February 22, 2025
Is the World on the Brink of Another Pandemic? Scientists Discover a New Bat VirusFebruary 22, 2025
Newcastle University Expands Academic and Research Collaborations in IndiaFebruary 21, 2025
Get Ready to #BibaUp! Kriti Sanon Unveils the Season’s Most Stylish Summer CollectionFebruary 21, 2025
A Rare Condition: Surgery Saves 2-Day-Old Baby as Organs Shift Into ChestFebruary 21, 2025
Odisha’s Bold Healthcare Vision: A Rs 12,000 Crore Blueprint for Universal Health AccessFebruary 21, 2025
Young India’s Health Crisis: Why Insurance Claims Are Rising Among 25-35 Year OldsFebruary 21, 2025
India vs. Trump’s Pharma Tariff: The Battle Over Affordable MedicineFebruary 21, 2025
Foreign Medical Aspirants in Trouble: NMC’s Warning on Pending Eligibility CertificatesFebruary 21, 2025
Think Your Work Music Helps You Focus? Science Says Think AgainFebruary 21, 2025
Is Your Home’s Air Poisoning You? Shocking New Study Reveals Hidden Indoor Pollution RisksFebruary 20, 2025
The Society of Automotive Engineers & B V Raju Institution of Technology; to host the globally prestigious E-BAJA 2025; at Hyderabad!February 20, 2025
Eat right for your heart to beat rightFebruary 19, 2025
Aakash Healthcare and Medtronic Inaugurate North India’s First Dedicated Vein ClinicFebruary 19, 2025
Urgent and accelerated HIV service delivery with equity and rights is critical to end AIDSFebruary 19, 2025
Fasting Fad or Future Health Threat? Why Teens Should Think Twice Before Intermittent Fasting February 19, 2025
Public Hospitals Go High-Tech: AIIMS Delhi Leads India’s Robotic Surgery WaveFebruary 19, 2025
Screen Time and Healthy Habits: Navigating Optimal Development in ChildrenFebruary 18, 2025
SRM Global Hospitals Launches WOW, a Centre Exclusively for Women’s Health and WellnessFebruary 18, 2025
The Hidden Dangers of Scented Candles: Aesthetic Bliss or Silent Health Hazard?February 18, 2025